BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993]
URL: https://www.wjgnet.com/1007-9327/full/v20/i8/1993.htm
Number Citing Articles
1
Dylan L. Schaff, Aria J. Fasse, Phoebe E. White, Robert J. Vander Velde, Sydney M. Shaffer. Clonal differences underlie variable responses to sequential and prolonged treatmentCell Systems 2024; 15(3): 213 doi: 10.1016/j.cels.2024.01.011
2
Alessandro Parisi, Alessio Cortellini, Katia Cannita, Olga Venditti, Floriana Camarda, Maria Alessandra Calegari, Lisa Salvatore, Giampaolo Tortora, Daniele Rossini, Marco Maria Germani, Alessandra Boccaccino, Emanuela Dell’Aquila, Claudia Fulgenzi, Daniele Santini, Michele De Tursi, Nicola Tinari, Pietro Di Marino, Pasquale Lombardi, Susana Roselló Keränen, Marisol Huerta Álvaro, Ina Valeria Zurlo, Domenico Cristiano Corsi, Alessandra Emiliani, Nicoletta Zanaletti, Teresa Troiani, Pasquale Vitale, Riccardo Giampieri, Filippo Merloni, Mario Alberto Occhipinti, Paolo Marchetti, Michela Roberto, Federica Mazzuca, Michele Ghidini, Alice Indini, Ingrid Garajova, Federica Zoratto, Simona Delle Monache, Giampiero Porzio, Corrado Ficorella. Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” StudyCancers 2020; 12(5): 1259 doi: 10.3390/cancers12051259
3
Chiara Guarini, Teresa Grassi, Gaetano Pezzicoli, Camillo Porta. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal CancerInternational Journal of Molecular Sciences 2021; 22(13): 6813 doi: 10.3390/ijms22136813
4
Laura A. Barufaldi, Rita de C.R. de Albuquerque, Aline do Nascimento, Luís Felipe L. Martins, Ivan R. Zimmermann, Mirian C. de Souza. Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal CancerValue in Health Regional Issues 2023; 37: 33 doi: 10.1016/j.vhri.2023.04.003
5
Koen Degeling, Hui-Li Wong, Hendrik Koffijberg, Azim Jalali, Jeremy Shapiro, Suzanne Kosmider, Rachel Wong, Belinda Lee, Matthew Burge, Jeanne Tie, Desmond Yip, Louise Nott, Adnan Khattak, Stephanie Lim, Susan Caird, Peter Gibbs, Maarten IJzerman. Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry DataPharmacoEconomics 2020; 38(11): 1263 doi: 10.1007/s40273-020-00951-1
6
Ruihua Xu, Shukui Qin, Weijian Guo, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Hongming Pan, Yongqian Shu, Ying Yuan, Jianfeng Zhou, Nong Xu, Tianshu Liu, Dong Ma, Changping Wu, Ying Cheng, Jianming Xu, Donghui Chen, Wei Li, Sanyuan Sun, Zhuang Yu, Peiguo Cao, Jian Li, Haihui Chen, Jiejun Wang, Shubin Wang, Hongbing Wang, Ning Wang, Bin Zhang, Rubing Han, Weiguo Su, Xiaojun Guo, Jin Li. Subgroup analysis by prior anti-VEGFor anti-EGFR target therapy in FRESCO,a randomized, double-blind, Phase III trialFuture Oncology 2021; 17(11): 1339 doi: 10.2217/fon-2020-0875
7
Alejo Albornoz, Romina Luca, Guillermo Méndez, Marcela Moreno, Federico Esteso, Luisina Bruno, Matías Chacón, Juan Manuel O’Connor. Reexposición de la terapia con Anti-EGFR en pacientes con cáncer colorrectal metastásico RAS/BRAF tipo salvajeOncología Clínica 2022; 26(1) doi: 10.56969/oc.v26i1.8
8
Mehmet Artaç, Hasan Şenol Coşkun, Faysal Dane, Bülent Karabulut, Levent Korkmaz, Mustafa Karaağaç, Devrim Çabuk, Senem Karabulut, Nuri Faruk Aykan, Hatice Doruk, Nilüfer Avcı, Nazım Serdar Turhal. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group StudyJournal of Gastrointestinal Cancer 2016; 47(3): 264 doi: 10.1007/s12029-016-9823-7
9
Tadeu Ferreira Paiva, Victor Hugo Fonseca de Jesus, Raul Amorim Marques, Alexandre André Balieiro Anastácio da Costa, Mariana Petaccia de Macedo, Patricia Maria Peresi, Aline Damascena, Benedito Mauro Rossi, Maria Dirlei Begnami, Vladmir Cláudio Cordeiro de Lima. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survivalBMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1648-4
10
Hye Lee, Eunju Son, Kyoungmin Lee, Yeri Lee, Yejin Kim, Jae-Chul Lee, Yangmi Lim, Minkyu Hur, Donggeon Kim, Do-Hyun Nam. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived XenograftsInternational Journal of Molecular Sciences 2019; 20(23): 5894 doi: 10.3390/ijms20235894
11
Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs, Maarten IJzerman. Health Economic Models for Metastatic Colorectal Cancer: A Methodological ReviewPharmacoEconomics 2020; 38(7): 683 doi: 10.1007/s40273-020-00908-4
12
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh. Vaccines for colorectal cancer: an updateJournal of Cellular Biochemistry 2019; 120(6): 8815 doi: 10.1002/jcb.28179
13
Se Hee Park, Kon-Young Ji, Hyun Min Kim, Sang Hoon Ma, Seo Young Park, Ju Hui Do, Doo-Byoung Oh, Hyung Sik Kang, Jae Sung Shim, Young Hee Joung. Optimization of the human colorectal carcinoma antigen GA733-2 production in tobacco plantsPlant Biotechnology Reports 2021; 15(1): 55 doi: 10.1007/s11816-020-00657-y
14
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancerMedicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531
15
Mingfu Tong, Haiming Liu, Jianyu Hao, Daiming Fan. Comparative pharmacoproteomics reveals potential targets for berberine, a promising therapy for colorectal cancerBiochemical and Biophysical Research Communications 2020; 525(1): 244 doi: 10.1016/j.bbrc.2020.02.052
16
Ayse Ocak Duran, Halit Karaca, Mehmet Besiroglu, Ibrahim Vedat Bayoglu, Serkan Menekse, Heves Surmeli Yapici, Dogan Yazilitas, Aykut Bahceci, Mukremin Uysal, Alper Sevinc, Ilhan Hacibekiroglu, Asude Aksoy, Ozgur Tanriverdi, Erkan Arpaci, Mevlude Inanc, Faysal Dane, Metin Ozkan. XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical OncologyAsian Pacific Journal of Cancer Prevention 2015; 15(23): 10375 doi: 10.7314/APJCP.2014.15.23.10375
17
Iakovos Toumazis, Murat Kurt, Artemis Toumazi, Loukia G. Karacosta, Changhyun Kwon. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal CancerMDM Policy & Practice 2017; 2(2): 238146831772965 doi: 10.1177/2381468317729650
18
Sally Temraz, Deborah Mukherji, Ali Shamseddine. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersInternational Journal of Molecular Sciences 2015; 16(9): 22976 doi: 10.3390/ijms160922976
19
D.P. Modest, S. Pant, A. Sartore-Bianchi. Treatment sequencing in metastatic colorectal cancerEuropean Journal of Cancer 2019; 109: 70 doi: 10.1016/j.ejca.2018.12.019
20
Orlando Jorge Martins Torres, Marcos Belotto de Oliveira, Paulo Cezar Galvão do Amaral, Eliza Dalsasso Ricardo, Agnaldo Soares Lima, Alexandre Prado de Resende, Renata D’Alpino Peixoto. Colorectal Cancer Liver Metastases2020; : 145 doi: 10.1007/978-3-030-25486-5_12
21
Abdosaleh Jafari, Sedighe Sadat Tabatabaei Far, Mehdi Dehghani, Ramin Ravangard. Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, IranCancer Control 2023; 30 doi: 10.1177/10732748231180679